Unique: Novavax plans to ship COVID-19 vaccines to Europe from late 2021


© Reuters. FILE PHOTO: Vials labelled “COVID-19 Coronavirus Vaccine” and sryinge are seen in entrance of displayed Novavax brand on this illustration

By Francesco Guarascio

BRUSSELS (Reuters) – Novavax (NASDAQ:) has advised the European Union it plans to start delivering its COVID-19 vaccine to the bloc in the direction of the top of this 12 months, new steerage that might result in a proper contract being signed as early as this week, an EU official advised Reuters.

A deal would see Novavax provide a complete of as much as 200 million doses of the vaccine, offering the EU with booster photographs to assist comprise the coronavirus and probably guard in opposition to new variants, in response to the official, who has direct data of the discussions.

Novavax reached a preliminary cope with the bloc in December, however a last settlement has been delayed as a result of the U.S. firm has struggled to supply some uncooked supplies, Reuters reported in March.

The EU official, who declined to be recognized as a result of the matter is confidential, mentioned Novavax nonetheless had manufacturing issues, however what had modified is that “now they’ve a supply schedule”.

Novavax advised the EU in conferences over the past two weeks that it deliberate to ship the primary small shipments in the direction of the top of this 12 months, with the majority to be delivered in 2022, in response to the official, who mentioned the photographs would complement an enormous deliberate provide of vaccines from Pfizer (NYSE:) and BioNTech.

A spokesman for the EU Fee, which co-leads talks with vaccine makers along with governments of the 27-nation bloc, declined to remark as a result of the matter is confidential.

Novavax mentioned its negotiations with the EU had been persevering with. It declined to remark concerning the deliveries timeline, manufacturing issues or whether or not a proper deal was imminent.

No matter a attainable deal, the EU’s purchases stay conditional on the regulatory approval of the Novavax vaccine, which has been assessed below a rolling assessment by the European Medicines Company (EMA) since February.

The EMA has not set a date for its determination on the vaccine, which has not but been accepted wherever on the earth.


The European Fee has repeatedly expressed confidence that it has secured sufficient doses to succeed in its aim of vaccinating no less than 70% of its grownup inhabitants by the top of July. The World Well being Group says about 70% of a inhabitants must be immunized to interrupt transmission.

The EU is subsequently now planning for the approaching years, to verify the bloc may have sufficient boosters if they’re wanted to assist maintain COVID-19 in verify and combat variants.

As a part of this technique the EU has already pencilled an enormous cope with Pfizer-BioNTech for the availability of as much as 1.8 billion doses of their vaccine in 2022 and 2023, the biggest contract ever signed worldwide with a maker of COVID-19 photographs.

Novavax’s protein-based vaccine represents an “different or a complement” to the mRNA shot produced by Pfizer, the EU official mentioned, though it will likely be accessible in a lot smaller quantities. Of the 200 million doses deliberate, half are non-compulsory and will be purchased by the EU at a later date if desired.

“We will definitely add different potential vaccines, for instance protein-based vaccines have additionally fairly a possible,” European Fee chief Ursula von der Leyen mentioned in late April when she introduced the cope with Pfizer was about to be signed.

French drugmaker Sanofi (NASDAQ:), in partnership with British agency GlaxoSmithKline (NYSE:), can be attempting to provide a protein-based COVID-19 vaccine and has already signed a provide cope with the EU. However their trials suffered a setback in December, delaying growth.

($1 = 0.8305 euros)

Supply hyperlink

Leave a reply